{"id":"flublok-quadrivalent-by-sanofi-inc","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"5-10","effect":"Injection site swelling"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5783405","moleculeType":null,"molecularWeight":"528.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hemagglutinin proteins from four influenza virus strains (two A strains and two B strains) manufactured in insect cells using baculovirus expression technology. These proteins are recognized by the immune system as foreign antigens, triggering both humoral and cellular immune responses that generate protective antibodies and memory immunity against the targeted influenza strains.","oneSentence":"Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:34.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults 18 years of age and older"}]},"trialDetails":[{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Flublok™ Quadrivalent by Sanofi, Inc.","genericName":"Flublok™ Quadrivalent by Sanofi, Inc.","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults 18 years of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}